{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:11:54Z","timestamp":1790719914502,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10928-018-9614-9","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T15:02:31Z","timestamp":1552316551000},"page":"211-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"46","author":[{"given":"May","family":"Garrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruiz-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Parivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"issue":"23","key":"9614_CR1","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","volume":"24","author":"H Bouchard","year":"2014","unstructured":"Bouchard H, Viskov C, Garcia-Echeverria C (2014) Antibody-drug conjugates\u2013a new wave of cancer drugs. Bioorg Med Chem Lett 24(23):5357\u20135363. https:\/\/doi.org\/10.1016\/j.bmcl.2014.10.021","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"9614_CR2","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","volume":"17","author":"AD Ricart","year":"2011","unstructured":"Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17(20):6417\u20136427. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0486","journal-title":"Clin Cancer Res"},{"issue":"2 Pt A","key":"9614_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","volume":"67","author":"B Shor","year":"2015","unstructured":"Shor B, Gerber HP, Sapra P (2015) Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol 67(2 Pt A):107\u2013116","journal-title":"Mol Immunol"},{"issue":"1","key":"9614_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","volume":"12","author":"JF DiJoseph","year":"2006","unstructured":"DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin\u2019s B-cell lymphoma. Clin Cancer Res 12(1):242\u2013249. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1905","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9614_CR5","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5):1807\u20131814. https:\/\/doi.org\/10.1182\/blood-2003-07-2466","journal-title":"Blood"},{"issue":"6","key":"9614_CR6","first-page":"74","volume":"5","author":"JF DiJoseph","year":"2008","unstructured":"DiJoseph JF, Khandke K, Dougher MM, Evans DY, Armellino DC, Hamann PR, Damle NK (2008) CMC-544 (inotuzumab ozogamicin): a CD22-targeted immunoconjugate of calicheamicin. Hematol Meet Rep 5(6):74\u201377","journal-title":"Hematol Meet Rep"},{"issue":"6","key":"9614_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00280-007-0560-2","volume":"61","author":"ER Boghaert","year":"2008","unstructured":"Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, Damle NK (2008) Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother Pharmacol 61(6):1027\u20131035","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"9614_CR8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V71.5.1480.1480","volume":"71","author":"DR Boue","year":"1988","unstructured":"Boue DR, LeBien TW (1988) Expression and structure of CD22 in acute leukemia. Blood 71(5):1480\u20131486","journal-title":"Blood"},{"issue":"7","key":"9614_CR9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, Fitzgerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121(7):1165\u20131174","journal-title":"Blood"},{"issue":"6","key":"9614_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","volume":"15","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J (2015) Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 15(6):323\u2013334. https:\/\/doi.org\/10.1016\/j.clml.2015.03.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"9614_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O\u2019Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"key":"9614_CR12","unstructured":"Besponsa (inotuzumab ozogamicin). Summary of Product Characteristics, Pfizer Inc, Sandwich, Kent, UK"},{"issue":"6","key":"9614_CR13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1991.tb03971.x","volume":"32","author":"L Aarons","year":"1991","unstructured":"Aarons L (1991) Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 32(6):669\u2013670","journal-title":"Br J Clin Pharmacol"},{"key":"9614_CR14","unstructured":"US Department of Health and Human Services (1999) Guidance for Industry: Population Pharmacokinetics. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/UCM072137.pdf . Accessed 7 Feb 2019"},{"key":"9614_CR15","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1038\/psp.2014.42","volume":"3","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N (2014) Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL. CPT Pharmacomet Syst Pharmacol 3:e144. https:\/\/doi.org\/10.1038\/psp.2014.42","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9614_CR16","unstructured":"Levi M, Li J, Frey N, Kheoh T, Ren S, Woo M, Joshi A, Valente N, Jumbe N, Charoin JE (2008) Characterization of the time-varying clearance of rituximab in non-Hodgkin\u2019s lymphoma patients using a population pharmacokinetic analysis. American Conference on Pharmacometrics 2008. http:\/\/tucson2008.go-acop.org\/pdfs\/Levi.pdf . Accessed 5 Feb 2016"},{"issue":"4","key":"9614_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421. https:\/\/doi.org\/10.1007\/s10928-008-9094-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9614_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic\u2013pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20(5):511\u2013528","journal-title":"J Pharmacokinet Biopharm"},{"issue":"29","key":"9614_CR19","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2010.30.2307","volume":"28","author":"SS Ramalingam","year":"2010","unstructured":"Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ (2010) Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 28(29):4507\u20134512. https:\/\/doi.org\/10.1200\/JCO.2010.30.2307","journal-title":"J Clin Oncol"},{"issue":"2","key":"9614_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"10","key":"9614_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633\u2013659","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9614-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:58:40Z","timestamp":1721066320000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["9614"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9614-9","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"2 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was funded by Pfizer Inc. All authors are employees of Pfizer Inc. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}